Blood cancer patients who are still having difficulty getting Evusheld can download the FDA’s revised Evusheld Fact Sheet for Health Providers and send it to their providers. The Fact Sheet now specifies that people who have “Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)” are “moderately or severely immunocompromised” and eligible for Evusheld. This language was added to the NIH Covid 19 Treatment Guidelines in August and the FDA has also adopted it. The FDA has also made clear that “[t]he conditions listed in the Fact Sheet for Health Care Providers are not intended to be an all-inclusive list. Patients with other conditions not listed may also have moderate to severe immune compromise and therefore be eligible for Evusheld therapy, assuming the remaining terms and conditions of the authorization are met.” (FDA 10/3/22 release.)

The “FDA continues to recommend Evusheld as an appropriate option for PrEP to prevent COVID-19, in combination with other preventative measures like getting vaccinated and boosted as recommended, as Evusheld still offers protection against many of the currently circulating variants and may offer protection against future variants.” (FDA 10/3/22 release.) As noted by the FDA, Evusheld is effective at reducing severe disease from the dominant variant BA.5 as well as BA.2, BA.2.12.1 and BA.4. According to the CDC’s Covid Variant Tracker, which is updated weekly, BA.5 caused 62.2% of sequenced U.S Covid cases during the week ending October 22, 2022.